Kyung Sook Kim – CEO, Corestem, South Korea
Dr Kyung Sook Kim, CEO of Corestem, explains how her company has been pioneering the Korean stem cell industry since its foundation in 2003. She also discusses reimbursement and regulation…
Address: 5F, DaeHan Bldg 201-6, Guui-Dong, Kwangjin-Gu Seoul,Republic of Korea
Tel: +82 2 456 3043
KRPIA represents Republic of Korean Research-based Pharmaceutical Industry Association. KRPIA is the association of research-based companies which deliver innovative new medicines to the market through incessant research endeavors. KRPIA was established in March 1999, consisting of 24 multinational research-based pharmaceutical companies operating in Republic of Korea. At present, KRPIA has 28 member companies which are taking the lead in the world’s pharmaceutical market. KRPIA believes ‘New Medicines, New Hope’ so it is devoted to providing new innovative drugs in Republic of Korea and disseminating pharmaceutical-related information. KRPIA members have the best possible conditions to research, develop, market and inform about their pharmaceuticals, thus ensuring broad and fast access for patients to the best medical treatment. The value of research based medicines for the Republic of Korean society is visible and recognized in a health system with the patient as priority. The Republic of Korean Research-based Pharmaceutical Industry Association is perceived as a responsible partner that makes a valuable contribution to society.Mision: Promote the development and prompt introduction of innovative new pharmaceuticals Enhance the ethical standards of the pharmaceutical industry Strengthen the pharmaceutical industry’s contribution to the advancement of public health Effectively disseminate pharmaceutical-related information and contribute to medical treatment for patients and public health promotion
Dr Kyung Sook Kim, CEO of Corestem, explains how her company has been pioneering the Korean stem cell industry since its foundation in 2003. She also discusses reimbursement and regulation…
Dr Jino Park, founder and CEO of P&K Skin Research Centre, offers his assessment of the success of the Korean pharmaceutical industry, and the potential cosmetic products of the future.…
Ji-Young Lee, senior director clinical operations, and general management & business administration Korea of PAREXEL Korea discusses the strengths of Korea’s clinical research environment, and how PAREXEL can leverage its…
* This interview was conducted before GE’s announcement of its divestment of the GE Biopharma business Francis Van Parys, president & CEO of GE Healthcare Korea discusses their ambitions to…
Young Kim, founder and CEO of Synex Consulting Ltd., a consulting firm assisting healthcare companies in introducing and marketing their products on the Korean market, discusses how Synex’s ICC (In-Country…
Min-Young Kim, general manager at Ipsen Korea discusses her strategy to refocus the Korean affiliate away from the toxin market and towards oncology and rare diseases. She also documents Ipsen’s…
Woosok Lee, CEO of Kolon Pharma, Kolon Life Science and Kolon TissueGene, offers his insights into the potential of their blockbuster product Invossa which could exceed USD five billion of…
Dr Jin San-Yoo, president and CEO of PharmAbcine, lifts the lid on the company’s combination therapy with MSD’s blockbuster oncology treatment Keytruda. Dr Yoo explains the rationale behind his decision…
Professor Dae Ho Lee has been researching and treating Korean cancer patients for more than 20 years and advises the current government on healthcare policy. He breaks down the benefits…
This week the Korean Ministry of Food and Drug Safety announced that as of 12th March 2019 a revised narcotics bill will go into effect that will allow imports of medical…
Dr Byung Guk Yang, CEO of Daewoong Bio, explains the challenges the Korean healthcare system is facing and how his experience in the public sector now helps him lead a…
YJ Kim, country manager at BD Korea, discusses the integration of Bard into BD at the local level. He also offers his insights into the challenges of approval and pricing…
See our Cookie Privacy Policy Here
